Validated biomarkers for treatment response in patients suffering from brain metastases are needed in daily clinical practice as they may improve survival by providing reliable prognostic information and allowing alternative therapies. This work presents a new analysis tool for an early and non-invasive evaluation of treatment response in patients with brain metastases. A set of twenty-five metastases from sixteen patients were examined by T1-weighted and diffusion magnetic resonance imaging before starting radiotherapy and at least once after treatment. Diffusion MRI can show a correlation between water diffusion variation within metastasis area and its clinical evolution. Images were co-registered to pretreatment scans. Diffusion changes,...
The parametric response map (PRM) was evaluated as an early surrogate biomarker for monitoring treat...
The efficiency of an oncological treatment regimen is often assessed by morphological criteria such ...
RATIONALE: Treatment of glioblastoma (GBM) remains challenging due in part to its histologic intratu...
AbstractPurposeTo evaluate the ability of functional diffusion mapping “fDM” to predict early treatm...
Functional diffusion map (fDM) has been recently reported as an early and quantitative biomarker of ...
AbstractFunctional diffusion map (fDM) has been recently reported as an early and quantitative bioma...
Functional diffusion map (fDM) has been recently re-ported as an early and quantitative biomarker of...
Functional diffusion mapping (fDM) has shown promise as a sensitive imaging biomarker for predicting...
AbstractProstate cancer (PCa) is the most commonly diagnosed cancer in American men with a subset in...
The authors report a case where a quantitative assessment of the apparent diffusion coefficient (ADC...
Background: Early diagnosis of brain tumors has significant effect on the treatment process. Brain m...
BACKGROUND: MRI-based diffusion-weighted imaging (DWI) visualizes the local differences in water dif...
An imaging biomarker that would provide for an early quantitative metric of clinical treatment respo...
AbstractA goal of oncology is the individualization of patient care to optimize therapeutic response...
A goal of oncology is the individualization of patient care to optimize therapeutic responses and mi...
The parametric response map (PRM) was evaluated as an early surrogate biomarker for monitoring treat...
The efficiency of an oncological treatment regimen is often assessed by morphological criteria such ...
RATIONALE: Treatment of glioblastoma (GBM) remains challenging due in part to its histologic intratu...
AbstractPurposeTo evaluate the ability of functional diffusion mapping “fDM” to predict early treatm...
Functional diffusion map (fDM) has been recently reported as an early and quantitative biomarker of ...
AbstractFunctional diffusion map (fDM) has been recently reported as an early and quantitative bioma...
Functional diffusion map (fDM) has been recently re-ported as an early and quantitative biomarker of...
Functional diffusion mapping (fDM) has shown promise as a sensitive imaging biomarker for predicting...
AbstractProstate cancer (PCa) is the most commonly diagnosed cancer in American men with a subset in...
The authors report a case where a quantitative assessment of the apparent diffusion coefficient (ADC...
Background: Early diagnosis of brain tumors has significant effect on the treatment process. Brain m...
BACKGROUND: MRI-based diffusion-weighted imaging (DWI) visualizes the local differences in water dif...
An imaging biomarker that would provide for an early quantitative metric of clinical treatment respo...
AbstractA goal of oncology is the individualization of patient care to optimize therapeutic response...
A goal of oncology is the individualization of patient care to optimize therapeutic responses and mi...
The parametric response map (PRM) was evaluated as an early surrogate biomarker for monitoring treat...
The efficiency of an oncological treatment regimen is often assessed by morphological criteria such ...
RATIONALE: Treatment of glioblastoma (GBM) remains challenging due in part to its histologic intratu...